Reports Q2 revenue $546.6M, consensus $476.84M. “We delivered outstanding results in the second quarter, with record Signatera (NTRA) growth and continued strength across our women’s health and organ health product lines,” said Steve Chapman, chief executive officer of Natera. “We’re raising our outlook for the year and advancing a robust pipeline of data and innovation to help even more patients in the future.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA: